Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis

BMC Genomics

Review

Mamdooh Gari¹  Farid Ahmed²  Muhammad Imran Naseer²  Muhammad Hussain Al-Qahtani²  Muhammad Faheem³  Asad Muhammad Ilyas³  Taha A Kumosani⁴  Sultan Ahmad⁵ 

[1] Centre of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, KSA;Centre of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, KSA;KACST Technology Innovation Center in Personalized Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia;Department of Biochemistry, King Abdulaziz University, Jeddah, KSA;Department of Biochemistry, King Abdulaziz University, Jeddah, KSA;King Fahd Medical Research Center, King Abdulaziz University, Jeddah, KSA;King Fahd Medical Research Center, King Abdulaziz University, Jeddah, KSA;

关键词: Acute myeloid leukemia;    Next generation sequencing;    Exome sequencing;    RNA-Seq;    AML prognosis;    Targeted AML therapy;   

DOI  :  10.1186/1471-2164-16-S1-S5

来源: Springer

【 摘 要 】

Acute myeloid leukemia (AML) is a clonal disorder of the blood forming cells characterized by accumulation of immature blast cells in the bone marrow and peripheral blood. Being a heterogeneous disease, AML has been the subject of numerous studies that focus on unraveling the clinical, cellular and molecular variations with the aim to better understand and treat the disease. Cytogenetic-risk stratification of AML is well established and commonly used by clinicians in therapeutic management of cases with chromosomal abnormalities. Successive inclusion of novel molecular abnormalities has substantially modified the classification and understanding of AML in the past decade. With the advent of next generation sequencing (NGS) technologies the discovery of novel molecular abnormalities has accelerated. NGS has been successfully used in several studies and has provided an unprecedented overview of molecular aberrations as well as the underlying clonal evolution in AML. The extended spectrum of abnormalities discovered by NGS is currently under extensive validation for their prognostic and therapeutic values. In this review we highlight the recent advances in the understanding of AML in the NGS era.

【 授权许可】

Unknown   
© Ilyas et al; licensee BioMed Central Ltd. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.